OakChart

BlossomHill Therapeutics Inc

BLSMHealthcare·Biotechnology·USA·Small·NASD·Nov 12 • 3:59 PM ET

14.84-1.21 (-7.57%)
2026-11-13 13:30 CET
Market cap
$471.69M
Revenue, TTM
0.00 USD m
Net income, TTM
-24.01 USD m
Free cash flow, TTM
- USD m
EPS diluted, TTM
-0.76
Price / earnings
-
Compare

Price

BLSM against its 20 and 50-day averages
Terms2050Beat
Patternshover a marker to name it
RS 0EPS -0.95Price-0.95-0.9415.0020.0025.00879K1.8MVolumeAug 26Sep 26Oct 26Nov 26BLSMclose 14.8420-day 14.4450-day 18.1214.8452w high 27.9952w low 11.0252-week range, not 3 months

47.0% under the 52-week high of 27.99 on 21 Sep 2026. 52-week low 11.02 on 5 Nov 2026. Last 15 sessions, 59.1% high to low

Volume 0.00× normal · the session has not printed · the line is the 50-bar volume average

Setup. RS line 0
CANSLIM 0 of 6 — fails: EPS Growth Qtr Over Qtr: High (>25%); 52-Week High/Low: 0-10% below High; Institutional Ownership: Over 50%; Average Volume: Over 200K — not on the tape: EPS Growth This Year: High (>25%); Performance: Year +50%
VCP 3 of 6 — fails: 52-Week High/Low: 0-10% below High — not on the tape: 200-Day Simple Moving Average: Price above SMA200; 50-Day Simple Moving Average: SMA50 above SMA200
Minervini 0 of 4 — fails: 52-Week High/Low: 0-10% below High — not on the tape: 200-Day Simple Moving Average: Price above SMA200; 50-Day Simple Moving Average: SMA50 above SMA200; Performance: Year +50%
Zanger 1 of 5 — fails: RSI (14): Not Oversold (>50); 20-Day High/Low: 0-5% below High; Relative Volume: Over 1.5 — not on the tape: 200-Day Simple Moving Average: Price above SMA200
Leaders 0 of 5 — fails: 50-Day Simple Moving Average: Price above SMA50; Average Volume: Over 500K; 52-Week High/Low: 0-10% below High — not on the tape: 200-Day Simple Moving Average: Price above SMA200; Performance: Year +50%
Breakout 0 of 4 — fails: 52-Week High/Low: New High; Relative Volume: Over 2; 50-Day Simple Moving Average: Price above SMA50 — not on the tape: 200-Day Simple Moving Average: Price above SMA200
Growth 0 of 4 — fails: EPS Growth Qtr Over Qtr: High (>25%) — not on the tape: EPS Growth This Year: High (>25%); EPS Growth Next Year: High (>25%); Return on Equity: Over +15%
Quality 1 of 5 — fails: Debt/Equity: Low (<0.1) — not on the tape: Return on Equity: Over +15%; Net Profit Margin: High (>20%); P/E: Under 25
Value 0 of 4 — fails: P/B: Under 2; Debt/Equity: Low (<0.1) — not on the tape: P/E: Under 15; Return on Equity: Over +15%
Income 0 of 4 — fails: Dividend Growth: Growing 2+ Years — not on the tape: Dividend Yield: Over 2%; Payout Ratio: Low (<20%); P/E: Under 25
Small Cap 1 of 4 — fails: Average Volume: Over 500K — not on the tape: 200-Day Simple Moving Average: Price above SMA200; Performance: Year +50%
Accumulation 1 of 4 — fails: Institutional Ownership: Over 30% — not on the tape: 200-Day Simple Moving Average: Price above SMA200; Performance: Year Up
Relative Strength 0 of 3 — fails: Average Volume: Over 500K — not on the tape: Performance: Year +100%; 200-Day Simple Moving Average: Price above SMA200

Profile

BLSM
52-week range, 23% of the way up
11.0227.99

Blossomhill Therapeutics, Inc. is a clinical-stage biopharmaceutical company. It engages in the development of small molecule medicines for unmet medical needs in cancer treatment. The company was founded on June 22, 2020 and is headquartered in San Diego, CA.

Employees63
IPOAug 07, 2026
ATR, 14d1.74
Rel volume0.00
Short float2.61%
Insider own28.93%
Inst own24.57%

Snapshot

6 groups

Valuation

Index-
Market Cap$471.69M
Enterprise Value269.88M
Income-
Sales-
Book / share6.68
Cash / share7.08
Dividend Est.-
Dividend TTM-
Dividend Ex-Date-
Dividend Gr. 3/5Y- -
Payout-
Employees63
IPOAug 07, 2026

Ratios

Price / earnings-
Forward price / earnings-
Price / earnings / growth-
Price / sales-
Price / book2.22
Price / cash2.10
Price / free cash flow-
Value / cash profit-
Value / sales-
Quick Ratio5.26
Current Ratio12.82
Debt / equity0.11
Long-term debt / equity0.10
Options and shortNo / Yes

Earnings

Earnings / share-
Earnings next year-
Earnings next quarter-0.95
Earnings this year-
Earnings next year-
Earnings growth, 5 years-
Past earnings growth- -
Past sales growth- -
Earnings vs last year-
Sales vs last year-
Earnings vs last quarter-130.67%
Sales vs last quarter-
EarningsNov 12 AMC
Surprise-45.38% -

Ownership

Insiders own28.93%
Insider trades20.55%
Institutions own24.57%
Institution trades18.11%
Return on assets-
Return on equity-
Return on capital-
Gross Margin-
Operating margin-
Profit Margin-
20-day average2.78%
50-day average-18.12%
200-day average-16.97%

Technical

Shares out31.58M
Shares floating22.59M
Short / float2.61%
Short ratio3.04
Short interest0.59M
52-week high27.99 -47.0%
52-week low11.02 +34.7%
Volatility13.26% 11.97%
Average range1.74
Strength index47.86
Market sensitivity-
Relative volume0.00
Avg Volume194.23K
Volume0

Performance

Perf Week20.16%
Perf Month-2.75%
Perf Quarter-8.28%
Perf Half Y-
Perf YTD-5.78%
Perf Year-
Perf 3Y-
Perf 5Y-
Perf 10Y-
Recommendation1.00
Target Price35.40
Prev Close14.84
Price14.84
Change %0.00%

Analyst ratings

latest 3 of 3
DateActionAnalystRating changeTargetImplied
Sep 01, 2026InitiatedJP MorganOverweight$28+88.7%
Sep 01, 2026InitiatedH.C. WainwrightBuy$35+135.8%
Sep 01, 2026InitiatedGuggenheimBuy$30+102.2%

Peers

Mkt cap
TickerCompanyMkt cap
AVBPArriVent BioPharma Inc706.02M
CGEMCullinan Therapeutics Inc661.54M
ORICORIC Pharmaceuticals Inc886.23M
BDTXBlack Diamond Therapeutics Inc89.17M
NUVBNuvation Bio Inc1.44B
KURAKura Oncology Inc700.18M
RLAYRelay Therapeutics Inc4.00B
IDYAIdeaya Biosciences Inc3.04B
ERASErasca Inc5.52B
TNGXTango Therapeutics Inc4.21B

Insider trading

7 filings
InsiderRelationshipDateTransactionCostSharesValueTotal heldForm
GORDON CARL LDirectorAug 10 '26Buy16.00625,00010,000,0002,714,279Aug 12 04:46 PM
ORBIMED ADVISORS LLCDirectorAug 10 '26Buy16.00625,00010,000,0002,714,279Aug 12 04:43 PM
Schmid John P.DirectorAug 10 '26Buy16.006,00096,0006,000Aug 10 06:35 PM
Chen BihuaDirectorAug 10 '26Buy16.00312,5005,000,0003,614,034Aug 10 06:32 PM
Keyes Jason AChief Financial OfficerAug 10 '26Buy16.0070011,200700Aug 10 06:27 PM
Liptak Vincent PaulGeneral CounselAug 07 '26Buy15.802,50039,500109,212Aug 10 06:26 PM
Liptak Vincent PaulGeneral CounselAug 10 '26Buy16.002,20035,200111,412Aug 10 06:26 PM

Held by

AUM
TickerCompanyAUM
VTIVanguard Morningstar Total Stock Market ETFAUM: 696.31B
VXFVanguard Extended Market Index ETFAUM: 30.79B
VTWOVanguard Russell 2000 Index ETFAUM: 16.90B
VTWGVanguard Russell 2000 Growth Index ETFAUM: 1.43B
VTWVVanguard Russell 2000 Value Index ETFAUM: 1.29B
VTHRVanguard Russell 3000 Index ETFAUM: 4.87B

Quarterly earnings

2026Q3 EPS -1.290 missed -0.887. Sales 0.00 matched 0.00
EPS
0.0000-8.7502026Q1 EPS -1.29826Q12026Q2 EPS -8.750 against -0.92626Q22026Q3 EPS -1.290 against -0.88726Q3
Sales, USD millions
0.890-0.892026Q1 sales 0.0026Q12026Q2 sales 0.00 against 0.0026Q22026Q3 sales 0.00 against 0.0026Q3

The outline behind the bar is the estimate. The filled bar is the print. Green beat it, red missed it.

PeriodReportedEPS adjustedEPS estEPS reportedSales act, USD mSales est, USD mSurpriseYear-ago quarterAnalystsNext session
2026Q3ended 2026-09-302026-11-12 16:30-1.290-0.887-0.7600.000.00EPS +45.4% · sales --5 EPS · 4 sales-
2026Q2ended 2026-06-302026-09-18 08:30-8.750-0.926-0.7480.000.00EPS +844.9% · sales --5 EPS · 3 salesOpen -0.07% vs SPY -0.17%. Close -4.03% vs SPY -0.12%
2026Q1ended 2026-03-312026-06-03 12:00-1.298--0.6610.00-EPS - · sales ----
2026Q4ended 2026-12-31---0.949--0.00EPS - · sales --5 EPS · 4 sales-
2027Q1ended 2027-03-31---0.920--0.00EPS - · sales -vs 2026Q1, year-ago quarter · EPS - · sales -4 EPS · 2 sales-
2027Q2ended 2027-06-30---0.883--0.00EPS - · sales -vs 2026Q2, year-ago quarter · EPS - · sales -4 EPS · 2 sales-
2027Q3ended 2027-09-30---0.825--0.00EPS - · sales -vs 2026Q3, year-ago quarter · EPS - · sales -4 EPS · 2 sales-
2027Q4ended 2027-12-31---0.830--0.00EPS - · sales -vs 2026Q4, year-ago quarter · EPS - · sales -4 EPS · 2 sales-

Annual earnings

The earnings feed came back with no years.

Quarterly results

2026Q3 revenue 0.00
Revenue, USD millions
0.890-0.892025Q1 revenue 0.0025Q12025Q2 revenue 0.0025Q22026Q1 revenue 0.0026Q12026Q2 revenue 0.0026Q22026Q3 revenue 0.0026Q3

From the quarterly statement. Not an estimate.

Estimate revisions

Latest snapshot of each period and type. 2026Q4 E -0.95 per share.
PeriodTypeScaleDateMeanvs prior date
2026Q4Eper share2026-11-13-0.950.0%
2026Q4Rper share2026-11-13-1.080.0%
2026Q4Sper share2026-11-130.00-
2026Q3Eper share2026-11-09-0.89+2.1%
2026Q3Rper share2026-09-21-0.92-0.4%
2026Q3Sper share2026-09-180.00-
2026Q2Eper share2026-08-31-0.93-
2026Q2Rper share2026-08-31-0.77-
2026Q2Sper share2026-08-310.00-

Estimate history

Annual
Metric20242025MRQ
EPS per share-0.966-1.905-
Sales USD millions00-
Shares million shares323232
Quarterly
MetricQ1 '25Q2 '25Q1 '26Q2 '26Q3 '26
EPS per share-0.33-0.417-0.661-0.748-0.76
Sales USD millions00000
Shares million shares3232323232

Income statement, annual

USD millions, except where the row names a unit. The percent under a figure is against the same period a year earlier. TTM has no earlier TTM to compare with, and a ratio or a margin has no change.
MetricTTM2025FY12/31/20252024FY12/31/2024
Total Revenue0.000.000.00
Cost of Goods Sold Incl. D&A0.000.44+25.7%0.35
Gross Profit0.00-0.44-0.35
Selling, General and Administrative Excl. Other25.4863.58+76.4%36.05
Research and Development21.9356.14+76.5%31.81
Other Operating Expense-0.000.00
Operating Income-25.48-64.02-36.40
Unusual Expense-0.000.00
Net Income Before Taxes-24.01-60.55-30.70
Income Taxes0.000.000.00
Consolidated Net Income-24.01-60.55-30.70
Net Income From Continuing Operations-24.01-60.55-30.70
Net Income-24.01-60.55-30.70
EPS (Recurring) per share-0.76-1.91-0.97
EPS (Basic, Before Extraordinaries) per share-0.76-1.91-0.97
EPS (Diluted) per share-0.76-1.91-0.97
EBITDA--63.58-36.05
Non-Operating Income (Expense)1.473.47-39.2%5.71
Other After Tax Adjustments-0.000.00
Stock Option Compensation Expense-1.09+118.0%0.50
Shares Outstanding million shares31.5831.780.0%31.78
Market Capitalization471.69471.69-

Income statement, quarterly

The feed stopped at 5 periods.
USD millions, except where the row names a unit. The percent under a figure is against the same period a year earlier. TTM has no earlier TTM to compare with, and a ratio or a margin has no change.
Metric2026Q39/30/20262026Q26/30/20262026Q13/31/20262025Q26/30/20252025Q13/31/2025
Total Revenue0.000.000.000.000.00
Cost of Goods Sold Incl. D&A0.000.12+20.0%0.12+33.3%0.100.09
Gross Profit0.00-0.12-0.12-0.10-0.09
Selling, General and Administrative Excl. Other25.4824.55+75.4%21.98+93.3%14.0011.37
Research and Development21.9321.36+70.5%19.90+107.9%12.539.57
Other Operating Expense-0.000.000.000.00
Operating Income-25.48-24.67-22.11-14.10-11.45
Unusual Expense-0.000.000.000.00
Net Income Before Taxes-24.01-23.76-21.01-13.24-10.48
Income Taxes0.000.000.000.000.00
Consolidated Net Income-24.01-23.76-21.01-13.24-10.48
Net Income From Continuing Operations-24.01-23.76-21.01-13.24-10.48
Net Income-24.01-23.76-21.01-13.24-10.48
EPS (Recurring) per share-0.76-0.75-0.66-0.42-0.33
EPS (Basic, Before Extraordinaries) per share-0.76-0.75-0.66-0.42-0.33
EPS (Diluted) per share-0.76-0.75-0.66-0.42-0.33
EBITDA--24.55-21.98-14.00-11.37
Non-Operating Income (Expense)1.470.91+5.8%1.10+12.2%0.860.98
Other After Tax Adjustments-0.000.000.000.00
Stock Option Compensation Expense-0.58+132.0%0.32+39.1%0.250.23
Shares Outstanding million shares31.5831.780.0%31.780.0%31.7831.78
Market Capitalization471.69679.24---

Balance sheet, annual

USD millions, except where the row names a unit. The percent under a figure is against the same period a year earlier. TTM has no earlier TTM to compare with, and a ratio or a margin has no change.
Metric2025FY12/31/20252024FY12/31/2024
Cash & Short Term Investments136.68+36.5%100.15
Short Term Receivables0.000.00
Inventories0.000.00
Other Current Assets2.14-46.9%4.03
Total Current Assets138.83+33.3%104.17
Net Property, Plant & Equipment21.65+1261.6%1.59
Total Investments and Advances0.000.00
Deferred Tax Assets4.33+2606.3%0.16
Other Assets2.50+145.1%1.02
Total Assets167.30+56.4%106.94
Short Term Debt Incl. Current Port. of LT Debt0.01-98.1%0.53
Accounts Payable2.31+171.8%0.85
Other Current Liabilities13.16+143.7%5.40
Total Current Liabilities15.48+128.7%6.77
Long Term Debt279.22+61.5%172.88
Provision for Risks Charges0.000.00
Deferred Tax Liabilities4.33+2606.3%0.16
Other Liabilities0.000.00
Total Liabilities299.03+66.3%179.82
Non-Equity Reserves0.000.00
Preferred Stock - Carrying Value0.000.00
Common Equity-131.73-72.88
Total Shareholders Equity-131.73-72.88
Accumulated Minority Interest0.000.00
Total Equity-131.73-72.88
Total Liabilities & Stockholders Equity167.30+56.4%106.94
Book Value Per Share per share-4.14-2.29
Tangible Book Value Per Share per share-4.14-2.29
Full-Time Employees people63-
Price to Book Ratio ratio-2.70-
Return on Assets %-44.16-
Return on Invested Capital %-41.06-30.69
Quick Ratio ratio8.9715.38
Current Ratio ratio8.9715.38

Cash flow, annual

USD millions, except where the row names a unit. The percent under a figure is against the same period a year earlier. TTM has no earlier TTM to compare with, and a ratio or a margin has no change.
MetricTTM2025FY12/31/20252024FY12/31/2024
Net Income--60.55-30.70
Depreciation-0.44+25.7%0.35
Deferred Taxes & Investment Tax Credit-0.000.00
Other Funds (Non Cash)-2.38+98.3%1.20
Funds from Operations--57.74-29.14
Extraordinary Item-0.000.00
Changes in Working Capital-10.81-2.27
Cash from Operating Activities--46.92-31.42
Capital Expenditures--1.07-0.09
Net Assets From Acquisitions-0.000.00
Sale of Fixed Assets and Businesses-0.000.00
Purchase or Sale of Investments-0.000.00
Purchase of Investments-0.000.00
Sale Or Maturity of Investments-0.000.00
Other Uses-0.000.00
Other Sources-0.000.00
Cash from Investing Activities--1.07-0.09
Cash Dividends Paid-0.000.00
Preferred Dividends (Cash Flow)-0.000.00
Change in Capital Stock-84.53+381.4%17.56
Repurchase of Common Pref Stock-0.000.00
Sale of Common Pref Stock-84.53+381.4%17.56
Proceedsfrom Stock Options-84.53+381.4%17.56
Issuance or Reduction of Debt, Net-0.000.00
Change in Long Term Debt-0.000.00
Issuance of Long Term Debt-0.000.00
Reduction of Long Term Debt-0.000.00
Net Financing Active Other Cash Flow-0.000.00
Other Financing Activities Uses-0.000.00
Cash from Financing Activities-84.53+381.4%17.56
Net Change in Cash-36.53-13.95
Free Cash Flow--47.99-31.51

Balance sheet, quarterly

The feed stopped at 5 periods.
USD millions, except where the row names a unit. The percent under a figure is against the same period a year earlier. TTM has no earlier TTM to compare with, and a ratio or a margin has no change.
Metric2026Q39/30/20262026Q26/30/20262026Q13/31/20262025Q22025Q1
Cash & Short Term Investments224.9195.38116.00--
Short Term Receivables-0.000.00--
Inventories-0.000.00--
Other Current Assets4.322.593.22--
Total Current Assets229.2397.97119.22--
Net Property, Plant & Equipment20.2820.6921.21--
Total Investments and Advances-0.000.00--
Other Assets2.485.482.98--
Total Assets251.98124.13143.41--
Short Term Debt Incl. Current Port. of LT Debt1.211.150.49--
Accounts Payable3.463.935.38--
Other Current Liabilities13.2113.5410.30--
Total Current Liabilities17.8818.6216.18--
Long Term Debt21.89279.05279.35--
Provision for Risks Charges-0.000.00--
Other Liabilities1.131.250.00--
Total Liabilities40.90298.91295.53--
Non-Equity Reserves-0.000.00--
Preferred Stock - Carrying Value0.000.000.00--
Common Equity211.08-174.78-152.12--
Total Shareholders Equity211.08-174.78-152.12--
Accumulated Minority Interest-0.000.00--
Total Equity211.08-174.78-152.12--
Total Liabilities & Stockholders Equity251.98124.13143.41--
Book Value Per Share per share6.68-5.50-4.79--
Tangible Book Value Per Share per share6.68-5.50-4.79--
Full-Time Employees people-6963--
Price to Book Ratio ratio-2.70-3.89---
Return on Invested Capital %-10.31-22.79-16.51--
Quick Ratio ratio-5.267.37--
Current Ratio ratio12.825.267.37--

Cash flow, quarterly

The feed stopped at 5 periods.
USD millions, except where the row names a unit. The percent under a figure is against the same period a year earlier. TTM has no earlier TTM to compare with, and a ratio or a margin has no change.
Metric2026Q32026Q26/30/20262026Q13/31/20262025Q26/30/20252025Q13/31/2025
Net Income--23.76-21.01-13.24-10.48
Depreciation-0.12+20.0%0.12+33.3%0.100.09
Other Funds (Non Cash)-0.98+75.0%0.65+58.5%0.560.41
Funds from Operations--22.66-20.23-12.59-9.98
Extraordinary Item-0.000.000.000.00
Changes in Working Capital--0.58-116.9%-0.703.44-1.00
Cash from Operating Activities--23.23-20.94-9.14-10.98
Capital Expenditures-0.00-0.01-0.59-0.40
Net Assets From Acquisitions-0.000.000.000.00
Sale of Fixed Assets and Businesses-0.000.000.000.00
Purchase or Sale of Investments-0.000.000.000.00
Purchase of Investments-0.000.000.000.00
Sale Or Maturity of Investments-0.000.000.000.00
Other Uses-0.000.000.000.00
Other Sources-0.000.000.000.00
Cash from Investing Activities-0.00-0.01-0.59-0.40
Cash Dividends Paid-0.000.000.000.00
Preferred Dividends (Cash Flow)-0.000.000.000.00
Change in Capital Stock-2.61+5120.0%0.27+575.0%0.050.04
Repurchase of Common Pref Stock-0.000.000.000.00
Sale of Common Pref Stock-2.61+5120.0%0.27+575.0%0.050.04
Proceedsfrom Stock Options-2.61+5120.0%0.27+575.0%0.050.04
Issuance or Reduction of Debt, Net-0.000.000.000.00
Change in Long Term Debt-0.000.000.000.00
Issuance of Long Term Debt-0.000.000.000.00
Reduction of Long Term Debt-0.000.000.000.00
Net Financing Active Other Cash Flow-0.000.000.000.00
Other Financing Activities Uses-0.000.000.000.00
Cash from Financing Activities-2.61+5120.0%0.27+575.0%0.050.04
Net Change in Cash--20.63-20.68-9.69-11.34
Free Cash Flow--23.23-20.95-9.74-11.38

Revenue breakdown

Revenue split-

Short interest

shares short against float, oldest to newest
SettlementOf floatShares shortFloatAvg volume
2026-10-302.61%0.6M22.6M226.76K
2026-10-152.15%0.5M22.6M248.62K
2026-09-302.13%0.5M22.3M271.18K
2026-09-150.62%0.1M22.3M261.47K
2026-08-310.52%0.1M21.5M321.54K
2026-08-140.52%0.1M21.4M613.09K

Option chain

expiry 2026-11-13
TypeStrikeBidAskLastIVOpen intVolumeDeltaThetaVega
No option chain for this symbol.

Latest SEC filings

30
FiledFormDescriptionPeriodLink
2026-11-1210-QQuarterly report pursuant to Section 13 or 15(d)2026-09-30SEC
2026-11-128-KCurrent report2026-11-12SEC
2026-09-1810-QQuarterly report pursuant to Section 13 or 15(d)2026-06-30SEC
2026-09-188-KCurrent report2026-09-18SEC
2026-09-158-KCurrent report2026-09-15SEC
2026-08-18SCHEDULE 13DSEC
2026-08-17SCHEDULE 13GSEC
2026-08-14SCHEDULE 13GSEC
2026-08-13SCHEDULE 13DSEC
2026-08-124Statement of changes in beneficial ownership of securities2026-08-10SEC
2026-08-124Statement of changes in beneficial ownership of securities2026-08-10SEC
2026-08-104Statement of changes in beneficial ownership of securities2026-08-06SEC
2026-08-104Statement of changes in beneficial ownership of securities2026-08-06SEC
2026-08-104Statement of changes in beneficial ownership of securities2026-08-06SEC
2026-08-104Statement of changes in beneficial ownership of securities2026-08-06SEC
2026-08-104Statement of changes in beneficial ownership of securities2026-08-06SEC
2026-08-104Statement of changes in beneficial ownership of securities2026-08-06SEC
2026-08-104Statement of changes in beneficial ownership of securities2026-08-10SEC
2026-08-104Statement of changes in beneficial ownership of securities2026-08-06SEC
2026-08-104Statement of changes in beneficial ownership of securities2026-08-06SEC
2026-08-10S-8Initial registration statement for securities to be offered to employees pursuant to employee benefit plansSEC
2026-08-108-KCurrent report2026-08-10SEC
2026-08-07424B4SEC
2026-08-06EFFECTEffectiveness filing by commission orderSEC
2026-08-063Initial statement of beneficial ownership of securities2026-08-06SEC
2026-08-063Initial statement of beneficial ownership of securities2026-08-06SEC
2026-08-063Initial statement of beneficial ownership of securities2026-08-06SEC
2026-08-063Initial statement of beneficial ownership of securities2026-08-06SEC
2026-08-063Initial statement of beneficial ownership of securities2026-08-06SEC
2026-08-063Initial statement of beneficial ownership of securities2026-08-06SEC

Insider activity by month

MonthBoughtBuysSoldSells
2026-110000
2026-100000
2026-090000
2026-0825.18M700
2026-070000
2026-060000
2026-050000
2026-040000
2026-030000
2026-020000
2026-010000
2025-120000
2025-110000

Institutional holders

Manager% owned
JPMORGAN CHASE & CO4.45%
FMR LLC3.23%
SILVERARC CAPITAL MANAGEMENT, LLC0.64%
GEODE CAPITAL MANAGEMENT, LLC0.37%
Monashee Investment Management LLC0.25%
Squarepoint Ops LLC0.07%
STATE STREET CORP0.05%
Aster Capital Management0.02%
CITIGROUP INC0.00%
UBS Group AG0.00%

Funds

Fund% owned
Select Biotechnology Portfolio1.13%
Multi-Manager Small Cap Equity Strategies Fund0.24%
Small Cap Value Fund0.06%
VANGUARD RUSSELL 2000 INDEX FUND0.03%
BlackRock Event Driven Equity Fund0.01%
VANGUARD RUSSELL 2000 GROWTH INDEX FUND0.00%
VANGUARD RUSSELL 2000 VALUE INDEX FUND0.00%
VANGUARD RUSSELL 3000 INDEX FUND0.00%

OakChart. BLSM. Cached 15 minutes. Terms

Some panels did not load: news.